Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis
Eva Stadler, Khai Li Chai, Timothy E. Schlub, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 11, pp. e883-e892
Open Access | Times Cited: 20

Showing 20 citing articles:

SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses
Marios Koutsakos, Arnold Reynaldi, Wen Shi Lee, et al.
Immunity (2023) Vol. 56, Iss. 4, pp. 879-892.e4
Open Access | Times Cited: 77
A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
Daniele Focosi, Arturo Casadevall
Viruses (2022) Vol. 14, Iss. 9, pp. 1999-1999
Open Access | Times Cited: 52
Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: a systematic review and meta-analysis
Karen M Elias, Shanchita R. Khan, Eva Stadler, et al.
The Lancet Microbe (2024) Vol. 5, Iss. 5, pp. e459-e467
Open Access | Times Cited: 10
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Computationally restoring the potency of a clinical antibody against Omicron
Thomas Desautels, Kathryn T. Arrildt, Adam Zemła, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 878-885
Open Access | Times Cited: 7
Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses
Annalisa Ciabattini, Elena Pettini, Fabio Fiorino, et al.
EBioMedicine (2025) Vol. 113, pp. 105577-105577
Open Access
Single Monoclonal Antibodies Should Not Be Used for Coronavirus Disease 2019 Therapy: A Call for Antiviral Stewardship
Arturo Casadevall, Daniele Focosi, Liise-anne Pirofski, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 6, pp. 1404-1407
Closed Access | Times Cited: 4
SARS-CoV-2 neutralizing antibody bebtelovimab – a systematic scoping review and meta-analysis
Mabel Nyit Yi Liew, Kok Pim Kua, Shaun Wen Huey Lee, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Association between COVID-19 convalescent plasma antibody levels and COVID-19 outcomes stratified by clinical status at presentation
Hyung Park, Chang Yu, Liise‐anne Pirofski, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
Massimo Franchini, Arturo Casadevall, Michael J. Joyner, et al.
Life (2023) Vol. 13, Iss. 1, pp. 134-134
Open Access | Times Cited: 9
A Web Tool to Estimate Baseline Anti-Spike Monoclonal Antibody Efficacy Based on Regional Genomic Surveillance
Daniele Focosi
Viruses (2023) Vol. 15, Iss. 5, pp. 1048-1048
Open Access | Times Cited: 9
Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review
Massimo Franchini, Daniele Focosi
Life (2024) Vol. 14, Iss. 2, pp. 214-214
Open Access | Times Cited: 2
An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity
Emma Chang-Rabley, Menno C. van Zelm, Emily Ricotta, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 675-675
Open Access | Times Cited: 1
Hyperimmune Plasma and Immunoglobulins Against COVID-19: A Narrative Review
Massimo Franchini, Daniele Focosi
(2023)
Open Access | Times Cited: 4
Fc-mediated functions and the treatment of severe respiratory viral infections with passive immunotherapy – a balancing act
Hillary A. Vanderven, Stephen J. Kent
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies
Andrea T. Hooper, Selin Somersan-Karakaya, Shane McCarthy, et al.
mBio (2022) Vol. 13, Iss. 6
Open Access | Times Cited: 7
Convalescent Plasma for Critically-ill Covid-19 Patients
Adel A. Aljatham, Waleed T. Hashim, Mohamad A. Almashiakhi, et al.
Research Square (Research Square) (2024)
Open Access
Longitudinal Immunogenicity Study of SARS-CoV-2 mRNA Vaccines Across Subjects with Different Immunocompromising Conditions: Heterogeneity in the Immune Response and Crucial Role of the Booster Dose
Annalisa Ciabattini, Elena Pettini, Fabio Fiorino, et al.
(2024)
Closed Access
Historical texts as a potential resource for plant-derived natural products against SARS-CoV-2 – the example of theReceptariumof Burkhard III von Hallwyl from 16th century Switzerland
Nina Vahekeni, Jonas Stehlin, Corinna Urmann, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients—authors’ response
Tzong‐Yow Wu, Pao-Yu Chen, Jann‐Tay Wang, et al.
Journal of Antimicrobial Chemotherapy (2024)
Closed Access
Page 1

Scroll to top